Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer
(NRG Oncology) Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Cervical Cancer | Clinical Trials | Immunotherapy | Women | Yervoy